Sabine D. Brookman-May, Professor of Urology at Universität München, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X about a paper by Meredith McKean et al. published in Journal of Clinical Oncology:
“Promising early results for zelenectide pevedotin (BT8009), a Nectin-4–targeting Bicycle Drug Conjugate, from the phase I/II Duravelo-1 trial:
- ORR 38% and CBR 57% in pretreated urothelial cancer
- Well-tolerated safety profile (MTD 7.5 mg/m² q2w)
Encouraging data that could position next-gen ADCs beyond EV as new options in advanced UC.”
Title: First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation
Authors: Capucine Baldini, Loic Verlingue, Vincent Goldschmidt, Bernard Doger de Spéville, Julia Lostes, Antoine Italiano, Sophie Cousin, Gerald S. Falchook, Andrea Necchi, Oscar Reig Torras, Elisa Fontana, Louise Carter, Jordi Rodon Ahnert, Jason R. Brown, Leslie R. DeMars, Kate Josephs, Amy Dickson, Cong Xu, Justin Bader, Carly Campbell, Rajiv Sharma, Meredith McKean.
You can read the full article in Journal of Clinical Oncology.
More posts featuring Sabine D. Brookman-May.